Barclays Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Equalweight

January 10, 2014 7:25 AM EST Send to a Friend
Get Alerts BMRN Hot Sheet
Price: $85.83 +1.66%

Rating Summary:
    13 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade BMRN Now!
Join SI Premium – FREE
Barclays downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Overweight to Equalweight with a price target of $73.00 (from $75.00).

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $70.18 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades

Related Entities

Barclays

Add Your Comment